FDA Advisors Reverse Decision on Weight-Loss Drug Qnexa

By Bizclik Editor

With the growing problem of obesity in the U.S. hastened by deep-seated roots stemming from a largely sedentary lifestyle and unhealthy eating habits, it’s no surprise that a quick-fix continues to be the elusive carrot on a stick.

Pharmaceutical giants, including Arena Pharmaceuticals, Lorcaserin and Vivus Inc., are jostling for the chance to be the first company to release an FDA-approved prescription weight-loss drug since the last, and only, approved prescription drug of its kind hit the market in 1999.

The search for a “magic pill” has been hindered in recent months as Vivus’ drug, Qnexa, was struck down by the FDA’s advisory committee last year, citing direct connections to heightened risk of cardiovascular problems and birth defects. In an apparent change of heart, a panel of medical experts released a 20-2 vote in favor of Qnexa Wednesday, likely meaning the FDA’s final decision later in the year will be to approve the drug.


First-ever Report Discusses Cost of Obesity to Americans

Fresh and Health Initiative via Vending Machines

Click here to read the latest edition of Business Review USA

The drug manufacturer, based out of Mountain View, California, addressed the original health concerns by proposing monthly pregnancy tests for patients administered the drug, as well as strictly controlled distribution by registered pharmacies and specialized training for healthcare providers to better educate them on the risks of the medication. Vivus also recommended implementing a program to closely monitor heart risks in patients using the drug.

"We are confident the Qnexa [risk management program] balances the safeguards while allowing access for appropriate patients,” Dr. Barbara Troupin, Vivus' senior director of global medical affairs, told the committee. Qnexa combines the appetite suppressant phentermine and anticonvulsant drug topiramate. Users lost an average of 10% of their body weight during clinical trials.

Over-the-counter weight loss supplements remain popular, despite recalls and negative side effects, including dozens of deaths linked to the Fen Phen craze of the ‘90s. Marketdata projects diet pill and meal replacement sales alone will total $3.04 billion in yearly sales by 2014.


Featured Articles

Top 10 wealthiest billionaires in the US

Business Chief provides a rundown of the top 10 richest billionaires in the US based on the most recent Forbes 400 list, which is published every year

Top 10 easiest countries in the world to do business

Business Chief takes a look at the top 10 places in the world to do business, according to TMF Group's Global Business Complexity Index (GBCI) for 2023

Patagonia Chair Charles Conn on becoming an imperfectionist

Entrepreneur and Patagonia Chair Charles Conn talks to Business Chief about rethinking strategy amid uncertainty, and why an imperfectionist approach works

Top 10 most valuable brands in the world – Amazon to TikTok

Corporate Finance

Four priorities for new Twitter CEO Linda Yaccarino

Leadership & Strategy

Top 10 shifts transforming organisations – McKinsey & Co

Leadership & Strategy